NCT07045168

Risk-adapted Therapeutic Strategy in +1q NDMM

Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: FengYan Jin · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
OTHER	risk-scoring model	This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.

Timeline

• Start date: 2025-09-15
• Primary completion: 2027-09-15
• Completion: 2029-07-04
• First posted: 2025-07-01
• Last updated: 2025-09-15

Locations

1 site across 1 country: China